Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Desta Z, Metzger IF, Thong N, Lu JB, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6813-6822. doi: 10.1128/AAC.01000-16. Print 2016 Nov.

2.

Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.

Fokina VM, Xu M, Rytting E, Abdel-Rahman SZ, West H, Oncken C, Clark SM, Ahmed MS, Hankins GD, Nanovskaya TN.

Drug Metab Dispos. 2016 Nov;44(11):1832-1838. Epub 2016 Aug 15.

PMID:
27528039
3.

Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Masters AR, Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z.

J Pharmacol Exp Ther. 2016 Aug;358(2):230-8. doi: 10.1124/jpet.116.232876. Epub 2016 Jun 2.

PMID:
27255113
4.

Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.

Cho DY, Shen JH, Lemler SM, Skaar TC, Li L, Blievernicht J, Zanger UM, Kim KB, Shin JG, Flockhart DA, Desta Z.

Drug Metab Pharmacokinet. 2016 Apr;31(2):107-16. doi: 10.1016/j.dmpk.2015.07.002. Epub 2015 Jul 29.

5.

Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.

Shu W, Guan S, Yang X, Liang L, Li J, Chen Z, Zhang Y, Chen L, Wang X, Huang M.

Br J Clin Pharmacol. 2016 Feb;81(2):327-40. doi: 10.1111/bcp.12800. Epub 2015 Dec 25.

6.

Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration.

Garcia KL, Coen K, Miksys S, Lê AD, Tyndale RF.

Neuropsychopharmacology. 2015 Jul;40(8):1910-8. doi: 10.1038/npp.2015.40. Epub 2015 Feb 5.

7.

Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes.

Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF.

Drug Metab Dispos. 2014 Nov;42(11):1971-7. doi: 10.1124/dmd.114.060285. Epub 2014 Sep 3.

8.

Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.

Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Dayer P, Walder B, Desmeules JA, Daali Y.

Clin Pharmacol Ther. 2014 Sep;96(3):349-59. doi: 10.1038/clpt.2014.83. Epub 2014 Apr 10.

9.

Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Deligiannidis KM, Byatt N, Freeman MP.

J Clin Psychopharmacol. 2014 Apr;34(2):244-55. doi: 10.1097/JCP.0000000000000087. Review.

10.

Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory.

Varshney E, Saha N, Tandon M, Shrivastava V, Ali S.

Springerplus. 2012 Oct 16;1:34. doi: 10.1186/2193-1801-1-34. eCollection 2012.

11.

CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.

Xu C, Quinney SK, Guo Y, Hall SD, Li L, Desta Z.

Drug Metab Dispos. 2013 Dec;41(12):2004-11. doi: 10.1124/dmd.113.051755. Epub 2013 Jul 11.

12.

High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6.

Twist GP, Gaedigk R, Leeder JS, Gaedigk A.

Pharmacogenomics. 2013 Jun;14(8):913-22. doi: 10.2217/pgs.13.66.

13.

Factors associated with discontinuation of bupropion and counseling among African American light smokers in a randomized clinical trial.

Nollen NL, Mayo MS, Ahluwalia JS, Tyndale RF, Benowitz NL, Faseru B, Buchanan TS, Cox LS.

Ann Behav Med. 2013 Dec;46(3):336-48. doi: 10.1007/s12160-013-9510-x.

14.

Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.

Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd.

Pharmacogenet Genomics. 2013 Mar;23(3):135-41. doi: 10.1097/FPC.0b013e32835d9ab0.

15.

The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.

Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD, Stewart PW, Lindley CM, Chen ML.

Drug Metab Dispos. 2013 Mar;41(3):575-81. doi: 10.1124/dmd.112.048108. Epub 2012 Dec 13.

16.

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.

Gervasini G, Vagace JM.

Front Genet. 2012 Nov 22;3:249. doi: 10.3389/fgene.2012.00249. eCollection 2012.

17.

Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation.

Martis S, Mei H, Vijzelaar R, Edelmann L, Desnick RJ, Scott SA.

Pharmacogenomics J. 2013 Dec;13(6):558-66. doi: 10.1038/tpj.2012.48. Epub 2012 Nov 20.

18.

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion.

Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF.

Clin Pharmacol Ther. 2012 Dec;92(6):771-7. doi: 10.1038/clpt.2012.186. Epub 2012 Nov 14.

19.

Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.

Bertrand J, Chou M, Richardson DM, Verstuyft C, Leger PD, Mentré F, Taburet AM, Haas DW; ANRS 12154 Study Group..

Pharmacogenet Genomics. 2012 Dec;22(12):868-76. doi: 10.1097/FPC.0b013e32835a5af2.

20.

Bioactivation of chlorpyrifos by CYP2B6 variants.

Crane AL, Klein K, Olson JR.

Xenobiotica. 2012 Dec;42(12):1255-62. doi: 10.3109/00498254.2012.702246. Epub 2012 Jul 10.

Supplemental Content

Support Center